The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy (Q28237978)

11

0 references

Giuseppe Remuzzi

object named as

Giuseppe Remuzzi

13

0 references

author name string

Dick de Zeeuw

1

0 references

Blai Coll

2

0 references

Dennis Andress

3

0 references

John J Brennan

4

0 references

Hui Tang

5

0 references

Mark Houser

6

0 references

Ricardo Correa-Rotter

7

0 references

Donald Kohan

8

0 references

Hiddo J Lambers Heerspink

9

0 references

Hirofumi Makino

10

0 references

Yili Pritchett

12

0 references

Robert Toto

15

0 references

Giancarlo Viberti

16

0 references

Hans-Henrik Parving

Journal of the American Society of Nephrology

17

0 references

language of work or name

English

0 references

publication date

May 2014

0 references

published in

0 references

volume

25

0 references

page(s)

1083-93

0 references

issue

5

0 references

cites work

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Endothelin antagonists for diabetic and non-diabetic chronic kidney disease

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Proteinuria should be used as a surrogate in CKD.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

The kidney in type 2 diabetes therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Avosentan for overt diabetic nephropathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Endothelin, hypertension and chronic kidney disease: new insights

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Liver toxicity of sitaxentan in pulmonary arterial hypertension

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4005314

Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease

27 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24722445

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1681/ASN.2013080830

1 reference

1146677

1146677

1 reference

1 reference

1 reference